Welcome to our dedicated page for Cassava Sciences SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cassava Sciences, Inc. (NASDAQ: SAVA) SEC filings page on Stock Titan aggregates the company’s official U.S. Securities and Exchange Commission disclosures, giving investors structured access to its regulatory record. Cassava is a clinical-stage biotechnology company based in Austin, Texas that focuses on developing simufilam, a proprietary, investigational oral small molecule for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy.
Through this page, readers can review Form 8-K current reports in which Cassava describes material events. Recent 8-K filings detail topics such as a binding term sheet to settle a consolidated securities class action for $31.25 million, the FDA’s decision to place the proposed proof-of-concept clinical trial of simufilam in TSC-related epilepsy on full clinical hold pending additional preclinical data and protocol modifications, and the dismissal of a criminal indictment against a former scientific collaborator. Other 8-Ks furnish earnings press releases, corporate presentations, and announcements regarding board appointments and executive compensation decisions tied to development and budgeting goals.
Investors can also connect these current reports with Cassava’s periodic filings, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which the company references in its risk factor and forward-looking statement discussions. These documents provide broader context on research and development spending, general and administrative expenses, cash and cash equivalents, and recorded loss contingencies related to securities litigation and regulatory matters.
Stock Titan’s platform supplements this raw filing data with AI-powered summaries that highlight the key points in lengthy documents, helping users quickly identify items related to clinical holds, settlement agreements, program discontinuations, and changes in leadership or governance. For those monitoring insider activity, real-time access to Form 4 insider transaction reports and other ownership-related filings is available, allowing a detailed view of equity movements by officers and directors alongside the company’s broader regulatory history.
Cassava Sciences filed an S-3 shelf registration for the primary offering of up to
Sales under the ATM may be made from time to time in transactions deemed an “at the market offering” pursuant to Rule 415. Cassava will pay Cantor up to
Unless otherwise stated in a supplement, proceeds are for general corporate purposes and working capital, and the ATM amount is included within the overall
Cassava Sciences reported Q3 2025 results. Operating expenses were
Cash and cash equivalents were
Cassava Sciences, Inc. filed a current report to note that it released a press release on November 12, 2025 covering its results of operations and financial condition. The company attached this press release as Exhibit 99.1 and stated that the information is being furnished, not filed, which limits how it is treated under securities law. The filing also identifies Cassava’s common stock, par value $0.001, as trading under the symbol SAVA on the NASDAQ Capital Market.
Cassava Sciences reported a legal update: on October 23, 2025, the U.S. District Court for the District of Maryland dismissed with prejudice the criminal indictment of Dr. Hoau‑Yan Wang, a former scientific collaborator and advisor to the company. A dismissal with prejudice permanently ends the case and prevents refiling of the same charges.
The company emphasized its support for scientific integrity and noted it is continuing its current program evaluating simufilam as a potential treatment for TSC‑related epilepsy, citing research conducted at numerous institutions. This update addresses a key legal overhang involving a third party while the company maintains focus on its development work.
Cassava Sciences (SAVA) reported a director stock option grant. On 10/21/2025, the director received a stock option for 53,000 shares with an exercise price of $3.98 per share and an expiration date of 10/21/2035. The option vests over three years at 1/36th each month. Following the grant, 53,000 derivative securities were beneficially owned, held directly. The grant price for the option was reported as $0.
Cassava Sciences (SAVA) filed a Form 3 initial statement of beneficial ownership. The reporting person is identified as a Director and reported no securities beneficially owned. The date of event is 10/21/2025.
The filing includes Exhibit 24 – Power of Attorney and was filed by one reporting person. This is an administrative disclosure and does not reflect a transaction.
Cassava Sciences expanded its Board of Directors to eight members and appointed Dawn Carter Bir as a Class I director, effective October 21, 2025. Her term will expire at the Company’s 2028 annual meeting of stockholders.
The Company stated there are no arrangements or understandings behind the appointment and no related‑party transactions requiring disclosure. Ms. Bir was made eligible for compensation under the Non‑employee Director Compensation Program and signed the Company’s standard indemnification agreement. A press release announcing the appointment was furnished as Exhibit 99.1.
Robert Christopher Cook, listed as Chief Operating & Legal Officer and a director of Cassava Sciences, Inc. (SAVA), reported an insider purchase on 09/30/2025. The Form 4 shows an acquisition of 13,725 shares of common stock at a price of $2.91 per share, and the filing reports 13,725 shares beneficially owned following the transaction. The report was signed under power of attorney on 10/02/2025.
Cassava Sciences insider purchase by CEO and director. Barry Richard, serving as President & CEO and a director, reported open-market purchases of 7,172 shares of Cassava Sciences Inc. (SAVA) on 09/22/2025 at a weighted average price of $2.28 per share (individual trades ranged $2.27–$2.29). After the transactions the reporting person beneficially owns 714,675 shares indirectly through a trust. The Form 4 was signed by power of attorney on 09/23/2025.
Cassava Sciences (SAVA) Director and President & CEO Barry Richard reported multiple open-market purchases of the company's common stock on September 18-19, 2025, acquiring a total of 237,941 shares at prices between $2.13 and $2.29. Following these transactions he beneficially owned 707,503 shares, held indirectly through a trust. The Form 4 was signed by an authorized POA on September 22, 2025.